EVIDENCE. COMPARISONS. CLEAR NEXT STEPS.FOR US CLINIC TEAMS PROCUREMENT RESEARCH
Market data and deal flow

What do prescription volumes and patient-use data reveal?

Dose Diligence research deskSection 11 · Page 4 of 11Last updated 17 Nov 2026

There is clear evidence of substantial utilization, but prescriptions, users and active patient-months are different units. Keep them separate in board materials and supplier negotiations.

IndicatorDated figureWhat it establishes—and what it does not
Tracked US incretin prescription-market growthLilly’s Q3 2026 presentation reports 32% market growth, using IQVIA weekly data through September 25, 2026.A tracked-market growth indicator, not a forecast for clinics. Lilly slides, October 29, 2026
Manufacturer concentration in that tracked marketLilly 63.0%; Novo Nordisk 36.6%, rolling four-week prescription shares through September 25, 2026.Concentration in the defined IQVIA incretin market; not a census of compounded supply. Lilly slides
US injectable Wegovy prescriptionsApproximately 4.1 million in Q3 2026; approximately 35% through self-pay.Manufacturer-reported channel activity; prescriptions are not unique patients. Novo Nordisk, November 4, 2026
US Wegovy pill prescriptionsApproximately 3.6 million in Q3 2026.Manufacturer-reported prescription volume, not continuous treatment or clinic-controlled purchasing. Novo Nordisk, November 4, 2026
Adults reporting GLP-1 use during the preceding year9.8%, with a 95% confidence interval of 9.0%–10.7%; survey conducted July–August 2025.Weighted survey estimate across indications, not current November 2026 prevalence. CDC, November 12, 2026
Compounded use among those survey respondents reporting GLP-1 use22.6%, with a 95% confidence interval of 18.9%–26.8%.Historical self-reported use; not current compounded-market share, lawful capacity or expenditure share. CDC, November 12, 2026

The CDC study used 8,118 completed surveys. Its recent publication date must not be confused with its older observation period. That distinction is particularly important when discussing compounded products after changes in shortage-related policy. CDC methods (cdc.gov)

Which volumes should a clinic request from a dispensing partner?

The desk recommends requesting the following, segmented by product, presentation and destination state:

  • Prescriptions received, accepted, rejected and dispensed.
  • Unique patients receiving a first shipment and a repeat shipment.
  • Days supplied, rather than only the number of prescriptions.
  • Median and high-percentile time from complete prescription to delivery.
  • Orders missing the agreed delivery window, with reason codes.
  • Refunds, reships and temperature-excursion replacements.
  • Patients transferred successfully when a route or partner changes.

These are proposed diligence measures—not published industry benchmarks. A supplier’s national prescription total does not answer whether it can support the clinic’s particular state, product and service requirements.

Explore the table row by row

A working view of the research

Tracked US incretin prescription-market growth

Dated figure
Lilly’s Q3 2026 presentation reports 32% market growth, using IQVIA weekly data through September 25, 2026.
What it establishes—and what it does not
A tracked-market growth indicator, not a forecast for clinics. Lilly slides, October 29, 2026

Sources cited on this page

  1. investor.lilly.com · Source 1 ↗https://investor.lilly.com/static-files/4580c401-611c-406b-8964-88cb8d887bd4
  2. sec.gov · Source 2 ↗https://www.sec.gov/Archives/edgar/data/353278/000162828026069805/caq32026.htm
  3. cdc.gov · Source 3 ↗https://www.cdc.gov/mmwr/volumes/75/wr/mm7544a1.htm
Section sources →